Innovation
2 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace active.
| Year | Filings |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
Investor mix
1 investor on record; lead investors include Beta Lab.
| Investor type | Count | Share |
|---|---|---|
| Accelerator & incubator | 1 | 100% |
Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and peptide payloads to specific cells at the right time.
2 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace active.
| Year | Filings |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
1 investor on record; lead investors include Beta Lab.
| Investor type | Count | Share |
|---|---|---|
| Accelerator & incubator | 1 | 100% |